These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20452618)

  • 1. Thromboresistant cardiopulmonary bypass circuits: room for improvement?
    Poynter JA
    J Surg Res; 2010 Oct; 163(2):e51-2. PubMed ID: 20452618
    [No Abstract]   [Full Text] [Related]  

  • 2. Multifactorial comparison of modified and conventional perfusion strategies in a porcine model of cardiopulmonary bypass.
    Hussaini BE; Treanor PR; Healey NA; Lu XG; Khuri SF; Thatte HS
    J Surg Res; 2011 Jun; 168(1):e7-15. PubMed ID: 20421111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation.
    Kuitunen AH; Heikkilä LJ; Salmenperä MT
    Ann Thorac Surg; 1997 Feb; 63(2):438-44. PubMed ID: 9033316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving cardiopulmonary bypass: heparin-coated circuits.
    Vocelka C; Lindley G
    J Extra Corpor Technol; 2003 Dec; 35(4):312-6. PubMed ID: 14979422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Heparin-Resistant Patients with Benefits? Maximizing Biocompatibility in Cardiopulmonary Bypass: Combining ATryn® Recombinant Antithrombin III and Carmeda® Heparin-Bonded Perfusion Circuits: A Case Series.
    Chryssos A; Stroup SJ; Pifer MM; Tawil M; Conrad CG
    J Extra Corpor Technol; 2015 Mar; 47(1):44-7. PubMed ID: 26390679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Con: heparin-bonded cardiopulmonary bypass circuits do not represent a desirable and cost-effective advance in cardiopulmonary bypass technology.
    Woolf RL; Mythen MG
    J Cardiothorac Vasc Anesth; 1998 Dec; 12(6):710-2. PubMed ID: 9854674
    [No Abstract]   [Full Text] [Related]  

  • 7. Stroke from heparin-coated circuits and reduced systemic anticoagulation.
    Dewanjee MK
    Ann Thorac Surg; 1997 Oct; 64(4):1218-9. PubMed ID: 9354569
    [No Abstract]   [Full Text] [Related]  

  • 8. Con: Heparin-bonded cardiopulmonary bypass circuits should be routine for all cardiac surgical procedures.
    Taneja R; Cheng DC
    Anesth Analg; 2006 Dec; 103(6):1370-2. PubMed ID: 17122205
    [No Abstract]   [Full Text] [Related]  

  • 9. Pro: Heparin-coated circuits should be used for cardiopulmonary bypass.
    Jessen ME
    Anesth Analg; 2006 Dec; 103(6):1365-9. PubMed ID: 17122204
    [No Abstract]   [Full Text] [Related]  

  • 10. Anticoagulation management during cardiopulmonary bypass in patients with antiphospholipid syndrome.
    Seki T; Shingu Y; Sugiki H; Wakasa S; Katoh H; Ooka T; Tachibana T; Kubota S; Matsui Y
    J Artif Organs; 2018 Sep; 21(3):363-366. PubMed ID: 29541945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro and con of heparin-bonded circuits for cardiopulmonary bypass.
    Weiss BM; von Segesser LK
    J Cardiothorac Vasc Anesth; 1999 Oct; 13(5):646-52. PubMed ID: 10527241
    [No Abstract]   [Full Text] [Related]  

  • 12. Pro: heparin-bonded circuits represent a desirable option for cardiopulmonary bypass.
    Shore-Lesserson L
    J Cardiothorac Vasc Anesth; 1998 Dec; 12(6):705-9. PubMed ID: 9854673
    [No Abstract]   [Full Text] [Related]  

  • 13. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descending thoracic aortic aneurysm repair with the aid of partial cardiopulmonary bypass: heparin-coated circuits versus nonheparin-coated circuits.
    Morishita K; Kawaharada N; Fukada J; Hachiro Y; Kurimoto Y; Fujisawa Y; Saito T; Abe T
    Artif Organs; 2005 Apr; 29(4):300-5. PubMed ID: 15787624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower dose of heparin for cardiopulmonary bypass is not necessarily associated with lower drainage loss.
    von Heymann C; Krimphove M; Spies C
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):727; author reply 728. PubMed ID: 15784394
    [No Abstract]   [Full Text] [Related]  

  • 16. TEG improves anticoagulation management during cardiopulmonary bypass complicated by antiphospholipid syndrome.
    Nakajima T; Kato H; Mathis BJ; Hiramatsu Y; Sakamoto H
    J Card Surg; 2020 Jun; 35(6):1354-1356. PubMed ID: 32302025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.
    Spanier TB; Oz MC; Minanov OP; Simantov R; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 May; 115(5):1179-88. PubMed ID: 9605089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery.
    Levy JH
    Semin Hematol; 1995 Oct; 32(4 Suppl 2):49-55. PubMed ID: 8821210
    [No Abstract]   [Full Text] [Related]  

  • 19. Factor XII Deficiency and Cardiopulmonary Bypass.
    Uppal V; Rosin M
    J Extra Corpor Technol; 2014 Sep; 46(3):254-7. PubMed ID: 26357792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More biocompatibility in cardiopulmonary bypass for high-risk patients.
    Baufreton C
    Ann Thorac Surg; 2006 Feb; 81(2):790-1; author reply 791. PubMed ID: 16427917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.